This is a translation of the Agreement It is prepared solely for convenience purposes. Please note that the Hebrew version constitutes the binding version, and in the event of any discrepancy, the Hebrew version shall prevail. Agreement Entered into...BioLight Life Sciences Ltd. • February 10th, 2016 • Surgical & medical instruments & apparatus
Whereas the Company wishes that Makov serve as acting Chairman of the Board of the Company, subject to receiving the approvals required under the Companies Law, 5759 – 1999 (hereinafter: the “Companies Law”);
Exhibit D [* * *] – CONFIDENTIAL TREATMENT REQUESTEDMutual Non-Disclosure Agreement • February 10th, 2016 • BioLight Life Sciences Ltd. • Surgical & medical instruments & apparatus
MUTUAL NON-DISCLOSURE AGREEMENT This Mutual Non-Disclosure Agreement (the “Agreement”) is made effective June 13, 2011 (the "Effective Date” by and between Aerie Pharmaceuticals, Inc., having its principal place of business at 1140 Route 22 East, Bridgewater, NJ 08807 ("Aerie") and Bio Light Israeli Life Sciences Investments Ltd., having a place of business at Paz Tower 7th Floor, 5-7 Shoham St., Ramat Gan Israel, 52521, on behalf of itself and its subsidiaries and affiliates ("Bio-Light") (collectively, “the parties”). The parties are evaluating the possibility of entering into a contractual arrangement relating to the evaluation by Bio-Light of Aerie's ocular drug implant/insert technology. In furtherance of that evaluation process and for such other purposes as the parties may agree in writing, the parties may wish to disclose to each other Proprietary Information (as described below). The parties acknowledge and agree that their relationship with respect to such discussions and oth
Micromedic Technologies Ltd. Options Agreement Made and executed in Ramat Gan on the 20th of March, 2012 BetweenOptions Agreement • February 10th, 2016 • BioLight Life Sciences Ltd. • Surgical & medical instruments & apparatus
Whereas: On March 20, 2012, the Company’s board of directors resolved, after receiving the approval of the audit committee dated February 14, 2012, to compensate the Offeree and grant him non-marketable options in the amount and price set forth in Appendix B to this Agreement (the “Options”), which are exercisable into ordinary shares par value NIS 1 each of the Company (the “Exercise Shares”), all under the option plan of the Company for 2010 (the “Option Plan”); and
This is a translation of the Agreement It is prepared solely for convenience purposes. Please note that the Hebrew version constitutes the binding version, and in the event of any discrepancy, the Hebrew version shall prevail. Agreement Entered into...BioLight Life Sciences Ltd. • February 10th, 2016 • Surgical & medical instruments & apparatus
Whereas the Company wishes that Makov serve as acting Chairman of the Board of the Company, subject to receiving the approvals required under the Companies Law, 5759 – 1999 (hereinafter: the “Companies Law”);
